|
|
Thank
you to our
sponsors. |
|
|
|
Founded
in 2004, BioStrategy Partners is a virtual
incubator providing technology and business
development services to emerging-stage life
sciences companies and university-based research
projects in the Greater Philadelphia
region. BioSP specializes in offering
business guidance and support to first-time
entrepreneurs, scientific founders, and
university-based principal
investigators. For more information,
please visit our web site, http://www.biostrategypartners.org. |
|
|
|
From
the Executive
Director
|
|
As
summer winds down and we gear up for back to
school and the fall season, please be sure to
check your inbox for information about BioSP's
Practical Knowledge Series of educational and
networking events. Our theme this year is
smart financial decision making for emerging
companies.
The
first session on September 11, 2009 is Company
Valuation: How and when to value your startup,
moderated by Maureen O'Leary, Ph.D. with a great
group of panelists lined up as you will see in the
program announcement below. On October 16th,
we'll cover markets and customers; on November
13th, license and option agreements, and on
December 18th, how to get your company off the
ground. And that's just the first half of
the Series! All programs are held in
Plymouth Meeting, conveniently located near the
turnpike and Route 476. So mark your
calendars and I look forward to seeing you on
September
11th. |
|
Upcoming
Programs |
|
Company
Valuation:
How
and When to Value Your
Startup
Friday,
September 11, 2009 8:30AM to
11:00AM
Citizens
Bank
Gateway
Center
Plymouth
Meeting, PA 19462
Moderator:
Maureen O'Leary,
Ph.D.
Stephen
Roth, Ph.D.,
President & CEO, Immune Control
Inc.
Jeffrey
H. Nicholas,
Chair of the Technology and Venture Finance Group,
Fox Rothschild
Scott
K. Dessain,
M.D., Ph.D., President and Chief Scientific
Officer, Immunome,
Inc.
Chris
Starr,
VP of Investments/Founder, The MAG Fund/Ben
Franklin
Technology
Partners |
|
A
Strategic Mechanism for Evaluating Inventions
Temple
University's
Office of Technology
Transfer |
|
Almost
every tech transfer office has a unique set of
guidelines in place to evaluate inventions coming
through its door. A diligent assessment eases the
GO/NO GO dilemma to a great extent. I would like
to share a few insights we have gathered at
Temple University's
Office of Technology Transfer from our experience
in evaluating and identifying the patent potential
of each
invention:
� A
meaningful discussion with the
inventors
After
a review of the submitted disclosure materials, a
one-on-one discussion is held with the inventors
to achieve the following: 1) a thorough
understanding of the invention; 2) teasing out
additional information regarding the intellectual
property and commercial potential of the
invention.
� Providing
a formal feedback to the
inventors
A
formal report listing prior art and the market
potential of the invention is provided to the
inventors. We call it Temple Invention Evaluation
Report (TIER). The report essentially asks the
inventors to differentiate their findings from the
prior art. This is a very useful mechanism in
carving out the intellectual property, and
answering the very important question: What are we
trying to
protect?
� Packaging
the disclosure
Based
on the feedback to the TIER, the disclosure is
retooled to include inter alia: 1) abstract of the
invention; 2) detailed description; 3) advantages
over the currently used technology;4)
applications; 5) academic and for-profit
competit
| | |
